Seroatlas · Human Serome Atlas

TRIP11

Thyroid receptor-interacting protein 11

Also known as: CEV14, GMAP-210, GMAP210, Trip230, TRIPB_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15643
Gene: TRIP11
Ensembl: ENSG00000100815
Chromosome: 14
Canonical length: 1979 aa
Protein class: Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location: Golgi apparatus,Primary cilium

OverviewNCBI Gene

This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.[provided by RefSeq, Mar 2010]

Canonical amino-acid sequenceUniProt

1979 residues, UniProt reviewed canonical sequence.

>Q15643|TRIP11
     1  MSSWLGGLGS GLGQSLGQVG GSLASLTGQI SNFTKDMLME GTEEVEAELP DSRTKEIEAI
    61  HAILRSENER LKKLCTDLEE KHEASEIQIK QQSTSYRNQL QQKEVEISHL KARQIALQDQ
   121  LLKLQSAAQS VPSGAGVPAT TASSSFAYGI SHHPSAFHDD DMDFGDIISS QQEINRLSNE
   181  VSRLESEVGH WRHIAQTSKA QGTDNSDQSE ICKLQNIIKE LKQNRSQEID DHQHEMSVLQ
   241  NAHQQKLTEI SRRHREELSD YEERIEELEN LLQQGGSGVI ETDLSKIYEM QKTIQVLQIE
   301  KVESTKKMEQ LEDKIKDINK KLSSAENDRD ILRREQEQLN VEKRQIMEEC ENLKLECSKL
   361  QPSAVKQSDT MTEKERILAQ SASVEEVFRL QQALSDAENE IMRLSSLNQD NSLAEDNLKL
   421  KMRIEVLEKE KSLLSQEKEE LQMSLLKLNN EYEVIKSTAT RDISLDSELH DLRLNLEAKE
   481  QELNQSISEK ETLIAEIEEL DRQNQEATKH MILIKDQLSK QQNEGDSIIS KLKQDLNDEK
   541  KRVHQLEDDK MDITKELDVQ KEKLIQSEVA LNDLHLTKQK LEDKVENLVD QLNKSQESNV
   601  SIQKENLELK EHIRQNEEEL SRIRNELMQS LNQDSNSNFK DTLLKEREAE VRNLKQNLSE
   661  LEQLNENLKK VAFDVKMENE KLVLACEDVR HQLEECLAGN NQLSLEKNTI VETLKMEKGE
   721  IEAELCWAKK RLLEEANKYE KTIEELSNAR NLNTSALQLE HEHLIKLNQK KDMEIAELKK
   781  NIEQMDTDHK ETKDVLSSSL EEQKQLTQLI NKKEIFIEKL KERSSKLQEE LDKYSQALRK
   841  NEILRQTIEE KDRSLGSMKE ENNHLQEELE RLREEQSRTA PVADPKTLDS VTELASEVSQ
   901  LNTIKEHLEE EIKHHQKIIE DQNQSKMQLL QSLQEQKKEM DEFRYQHEQM NATHTQLFLE
   961  KDEEIKSLQK TIEQIKTQLH EERQDIQTDN SDIFQETKVQ SLNIENGSEK HDLSKAETER
  1021  LVKGIKEREL EIKLLNEKNI SLTKQIDQLS KDEVGKLTQI IQQKDLEIQA LHARISSTSH
  1081  TQDVVYLQQQ LQAYAMEREK VFAVLNEKTR ENSHLKTEYH KMMDIVAAKE AALIKLQDEN
  1141  KKLSTRFESS GQDMFRETIQ NLSRIIREKD IEIDALSQKC QTLLAVLQTS STGNEAGGVN
  1201  SNQFEELLQE RDKLKQQVKK MEEWKQQVMT TVQNMQHESA QLQEELHQLQ AQVLVDSDNN
  1261  SKLQVDYTGL IQSYEQNETK LKNFGQELAQ VQHSIGQLCN TKDLLLGKLD IISPQLSSAS
  1321  LLTPQSAECL RASKSEVLSE SSELLQQELE ELRKSLQEKD ATIRTLQENN HRLSDSIAAT
  1381  SELERKEHEQ TDSEIKQLKE KQDVLQKLLK EKDLLIKAKS DQLLSSNENF TNKVNENELL
  1441  RQAVTNLKER ILILEMDIGK LKGENEKIVE TYRGKETEYQ ALQETNMKFS MMLREKEFEC
  1501  HSMKEKALAF EQLLKEKEQG KTGELNQLLN AVKSMQEKTV VFQQERDQVM LALKQKQMEN
  1561  TALQNEVQRL RDKEFRSNQE LERLRNHLLE SEDSYTREAL AAEDREAKLR KKVTVLEEKL
  1621  VSSSNAMENA SHQASVQVES LQEQLNVVSK QRDETALQLS VSQEQVKQYA LSLANLQMVL
  1681  EHFQQEEKAM YSAELEKQKQ LIAEWKKNAE NLEGKVISLQ ECLDEANAAL DSASRLTEQL
  1741  DVKEEQIEEL KRQNELRQEM LDDVQKKLMS LANSSEGKVD KVLMRNLFIG HFHTPKNQRH
  1801  EVLRLMGSIL GVRREEMEQL FHDDQGGVTR WMTGWLGGGS KSVPNTPLRP NQQSVVNSSF
  1861  SELFVKFLET ESHPSIPPPK LSVHDMKPLD SPGRRKRDTN APESFKDTAE SRSGRRTDVN
  1921  PFLAPRSAAV PLINPAGLGP GGPGHLLLKP ISDVLPTFTP LPALPDNSAG VVLKDLLKQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIP11 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.52
Highest tissue expression: 24 nTPM

Expression across tissuesHPA

Tissue

pancreas: 24 nTPM
parathyroid gland: 18 nTPM
thyroid gland: 16 nTPM
tongue: 15 nTPM
stomach: 15 nTPM
testis: 13 nTPM

Single-cell type

corticotrophs: 228 nCPM
somatotrophs: 186 nCPM
myonuclei: 183 nCPM
prostatic glandular cells: 177 nCPM
lacrimal acinar cells: 169 nCPM
salivary acinar cells: 165 nCPM

Immune cell

naive B-cell: 24 nTPM
eosinophil: 20 nTPM
non-classical monocyte: 16 nTPM
naive CD8 T-cell: 15 nTPM
NK-cell: 15 nTPM
memory CD4 T-cell: 15 nTPM

Brain region

choroid plexus: 48 nTPM
cerebellum: 42 nTPM
white matter: 41 nTPM
basal ganglia: 37 nTPM
midbrain: 35 nTPM
cerebral cortex: 34 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRIP11.

Disease | AllUniProt

Conditions TRIP11 is implicated in, by any mechanism.

Achondrogenesis 1A (ACG1A) MIM:200600
Odontochondrodysplasia 1 (ODCD1) MIM:184260

Disease | GeneticClinVar

90 pathogenic / likely-pathogenic of 1,065 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Achondrogenesis, type IA
Odontochondrodysplasia 1
Connective tissue disorder
TRIP11-related disorder
See cases

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.5
gnomAD pLI: 0
gnomAD missense Z: 0.52
DepMap mean gene effect: -0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

GRIP domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRIP11 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIP11 as an antibody target. Whether an autoantibody or antibody against TRIP11 could matter depends on whether native TRIP11 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIP11 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIP11 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...